AU2021338014A1 - Novel endo-β-N-acetylglucosaminidase - Google Patents
Novel endo-β-N-acetylglucosaminidase Download PDFInfo
- Publication number
- AU2021338014A1 AU2021338014A1 AU2021338014A AU2021338014A AU2021338014A1 AU 2021338014 A1 AU2021338014 A1 AU 2021338014A1 AU 2021338014 A AU2021338014 A AU 2021338014A AU 2021338014 A AU2021338014 A AU 2021338014A AU 2021338014 A1 AU2021338014 A1 AU 2021338014A1
- Authority
- AU
- Australia
- Prior art keywords
- leu
- asp
- ala
- ser
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020-147745 | 2020-09-02 | ||
| JP2020147745 | 2020-09-02 | ||
| PCT/JP2021/032083 WO2022050300A1 (ja) | 2020-09-02 | 2021-09-01 | 新規エンド－β－Ｎ－アセチルグルコサミニダーゼ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021338014A1 true AU2021338014A1 (en) | 2023-03-09 |
Family
ID=80492267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021338014A Pending AU2021338014A1 (en) | 2020-09-02 | 2021-09-01 | Novel endo-β-N-acetylglucosaminidase |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240336907A1 (https=) |
| EP (1) | EP4209506A4 (https=) |
| JP (1) | JP7798773B2 (https=) |
| KR (1) | KR20230061360A (https=) |
| CN (1) | CN116113641A (https=) |
| AU (1) | AU2021338014A1 (https=) |
| CA (1) | CA3191395A1 (https=) |
| TW (1) | TW202227479A (https=) |
| WO (1) | WO2022050300A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312728A (en) | 2021-11-30 | 2024-07-01 | Daiichi Sankyo Co Ltd | Protease-cleavable masked antibodies |
| TW202342106A (zh) | 2022-02-09 | 2023-11-01 | 日商第一三共股份有限公司 | 環境應答性遮蔽抗體及其利用 |
| CN118804983A (zh) | 2022-03-02 | 2024-10-18 | 第一三共株式会社 | 含Fc分子的制造方法 |
| KR20250054799A (ko) | 2022-08-29 | 2025-04-23 | 다이이찌 산쿄 가부시키가이샤 | 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트 |
| KR20250064682A (ko) | 2022-09-09 | 2025-05-09 | 다이이찌 산쿄 가부시키가이샤 | 신규 올리고당, 그 올리고당의 제조 중간체, 및 그것들의 제조 방법 |
| JP2024054523A (ja) * | 2022-10-05 | 2024-04-17 | 日本マイクロバイオファーマ株式会社 | 抗体薬物複合体の製造方法及びそれに用いる酵素 |
| KR20250138255A (ko) | 2023-01-27 | 2025-09-19 | 다이이찌 산쿄 가부시키가이샤 | 항 lrrc15 항체 |
| WO2025148976A1 (zh) * | 2024-01-10 | 2025-07-17 | 上海齐鲁制药研究中心有限公司 | 新型beta-N-乙酰氨基葡萄糖苷内切酶及其用途 |
| CN118308329B (zh) * | 2024-06-11 | 2024-08-06 | 中国海洋大学 | β-N-乙酰氨基己糖苷酶D297K及其应用 |
| CN118325869B (zh) * | 2024-06-12 | 2024-10-22 | 上海盛迪医药有限公司 | 一种内-β-N-乙酰葡糖苷酶变体 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2795349C (en) | 2010-04-15 | 2016-11-29 | Seattle Genetics, Inc. | Targeted pyrrolobenzodiazepine conjugates |
| IN2014DN06806A (https=) | 2012-02-10 | 2015-05-22 | Univ Maryland | |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| US9695212B2 (en) | 2012-12-13 | 2017-07-04 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| EP2934598B1 (en) | 2012-12-19 | 2018-04-18 | Board Of Regents, The University Of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
| ES2731681T3 (es) | 2013-02-22 | 2019-11-18 | Abbvie Stemcentrx Llc | Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos |
| US9840533B2 (en) | 2013-04-29 | 2017-12-12 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| WO2014189806A1 (en) | 2013-05-18 | 2014-11-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| KR20160047567A (ko) | 2013-08-28 | 2016-05-02 | 스템센트알엑스 인코포레이티드 | 조작된 항-dll3 접합체 및 사용 방법 |
| WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015074145A1 (en) | 2013-11-22 | 2015-05-28 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
| KR102337414B1 (ko) | 2013-12-16 | 2021-12-10 | 제넨테크, 인크. | 펩타이드 모방체 화합물 및 이의 항체-약물 컨쥬게이트 |
| CR20160564A (es) | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| DE102014214408A1 (de) | 2014-07-23 | 2016-01-28 | Wacker Chemie Ag | Härtbare Organopolysiloxanzusammensetzungen |
| BR102014018190B1 (pt) | 2014-07-24 | 2020-10-20 | Fabio Eduardo Sabonge Cunha | suporte para placa de sinalização vertical |
| WO2016036804A1 (en) | 2014-09-03 | 2016-03-10 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
| EP4530348A3 (en) | 2014-12-15 | 2025-08-06 | Basf Se | Detergent composition comprising subtilase variants |
| EA035817B1 (ru) | 2015-03-10 | 2020-08-14 | Адуро Байотек, Инк. | Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона" |
| SMT202000614T1 (it) | 2015-06-29 | 2021-01-05 | Immunogen Inc | Coniugati di anticorpi ingegnerizzati con cisteina |
| JP6744738B2 (ja) * | 2015-06-29 | 2020-08-19 | 公益財団法人野口研究所 | グライコシンターゼ |
| SG10202005460RA (en) | 2015-06-30 | 2020-07-29 | Seattle Genetics Inc | Anti-ntb-a antibodies and related compositions and methods |
| CN108026518B (zh) * | 2015-07-16 | 2022-09-06 | 第一三共株式会社 | 新型endos突变型酶 |
| GB201513607D0 (en) | 2015-07-31 | 2015-09-16 | Feingold Jay M | Pyrrolobenzodiazepine-antibody conjugates |
| KR102222186B1 (ko) | 2015-08-13 | 2021-03-03 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
| JP2018534295A (ja) | 2015-10-28 | 2018-11-22 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法 |
| CN107849084B (zh) | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
| DE212016000029U1 (de) | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
| KR102789862B1 (ko) | 2016-01-11 | 2025-04-03 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드 |
| WO2017124084A1 (en) | 2016-01-15 | 2017-07-20 | University Of Maryland, College Park | Endo-s2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins |
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| PT3440076T (pt) | 2016-04-07 | 2022-07-29 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas úteis como modeladores de proteína |
| WO2018003983A1 (ja) | 2016-07-01 | 2018-01-04 | 第一三共株式会社 | ｈＡＮＰ－Ｆｃ含有分子コンジュゲート |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| IL264049B2 (en) | 2016-07-06 | 2023-11-01 | Sperovie Biosciences Inc | Compounds, preparations and methods for treating the disease |
| WO2018039373A1 (en) | 2016-08-24 | 2018-03-01 | Cho Pharma Inc | Endoglycosidase mutants for glycoprotein remodeling and methods of using it |
| US20190345191A1 (en) | 2016-08-31 | 2019-11-14 | Innate Tumor Immunity, Inc. | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
| US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
| PT3523287T (pt) | 2016-10-04 | 2021-10-06 | Merck Sharp & Dohme | Compostos de benzo[b]tiofeno como agonistas de sting |
| US11001605B2 (en) | 2016-10-07 | 2021-05-11 | Biolog Life Science Institute Gmbh & Co. Kg | Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways |
| US11242593B2 (en) | 2016-11-30 | 2022-02-08 | Jfe Steel Corporation | Steel for nitrocarburizing, and component |
| PE20210255A1 (es) | 2016-12-01 | 2021-02-10 | Takeda Pharmaceuticals Co | Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon) |
| NZ762505A (en) * | 2017-09-29 | 2026-03-27 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| TW202504930A (zh) * | 2018-06-27 | 2025-02-01 | 台灣浩鼎生技股份有限公司 | 用於糖蛋白工程的糖苷合成酶變體及其使用方法 |
| JP7510249B2 (ja) | 2018-07-28 | 2024-07-03 | 公益財団法人野口研究所 | 複合型糖鎖を遊離する方法 |
| EP3848054B1 (en) * | 2018-09-06 | 2025-01-29 | Daiichi Sankyo Company, Limited | Antibody-drug conjugates of cyclic dinucleotide derivatives |
| JP6732150B1 (ja) | 2019-03-06 | 2020-07-29 | 東京インキ株式会社 | 熱ラミネート用スチレンフィルム用グラビア印刷インキ組成物 |
-
2021
- 2021-09-01 WO PCT/JP2021/032083 patent/WO2022050300A1/ja not_active Ceased
- 2021-09-01 CA CA3191395A patent/CA3191395A1/en active Pending
- 2021-09-01 CN CN202180054259.2A patent/CN116113641A/zh active Pending
- 2021-09-01 EP EP21864357.5A patent/EP4209506A4/en active Pending
- 2021-09-01 JP JP2022546941A patent/JP7798773B2/ja active Active
- 2021-09-01 AU AU2021338014A patent/AU2021338014A1/en active Pending
- 2021-09-01 TW TW110132419A patent/TW202227479A/zh unknown
- 2021-09-01 KR KR1020237006587A patent/KR20230061360A/ko active Pending
- 2021-09-01 US US18/024,258 patent/US20240336907A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3191395A1 (en) | 2022-03-10 |
| EP4209506A1 (en) | 2023-07-12 |
| CN116113641A (zh) | 2023-05-12 |
| JPWO2022050300A1 (https=) | 2022-03-10 |
| JP7798773B2 (ja) | 2026-01-14 |
| KR20230061360A (ko) | 2023-05-08 |
| US20240336907A1 (en) | 2024-10-10 |
| WO2022050300A1 (ja) | 2022-03-10 |
| TW202227479A (zh) | 2022-07-16 |
| EP4209506A4 (en) | 2024-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021338014A1 (en) | Novel endo-β-N-acetylglucosaminidase | |
| Giddens et al. | Endo-F3 glycosynthase mutants enable chemoenzymatic synthesis of core-fucosylated triantennary complex type glycopeptides and glycoproteins | |
| KR102546854B1 (ko) | 신규 EndoS 변이 효소 | |
| Wei et al. | Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation | |
| JP7047425B2 (ja) | 抗体の分離能が向上したＦｃ結合性タンパク質およびそれを用いた抗体の分離方法 | |
| BR112014019825B1 (pt) | Glicoengenharia quimioenzimática de anticorpos e fragmentos fc dos mesmos | |
| JP2008538926A (ja) | 切断可能なリンカーを有する一本鎖抗体 | |
| CN113754739B (zh) | 一种冠状病毒s蛋白rbd糖蛋白的制备方法及其应用 | |
| CN104098698B (zh) | 一种抗cd3抗体及其制法和应用 | |
| WO2019234021A1 (en) | Glycoengineered monoclonal antibody | |
| JP2016082962A (ja) | 糖鎖切断抗体の製造方法及び均一糖鎖抗体 | |
| US20230073926A1 (en) | Highly sialylated multimeric binding molecules | |
| WO2023104128A1 (zh) | 具有改变的糖基化修饰的Fc多肽 | |
| CA3239224A1 (en) | Compositions comprising enhanced multispecific binding agents for an immune response | |
| KR101755430B1 (ko) | 개선된 효율을 갖는 시알산전달효소를 이용한 당단백질의 당사슬에 시알산을 부가하는 방법 | |
| HK40096983A (en) | Novel endo-?-n-acetylglucosaminidase | |
| KR20230129484A (ko) | 4-1bb와 특이적으로 결합하는 항체 및 그 항원 결합단편 | |
| AU2017348982A1 (en) | Aglycosylated antibody Fc region for treating cancer | |
| WO2015102501A1 (en) | Method for industrial scale production of therapeutically active proteins of desired glycosylation pattern | |
| Al-Kinani | Modifying the Fc Asn297 Glycan of Human IgG2 Subclass for Improved Antibody Therapeutics and Design of Site-Specific Antibody Drug Conjugates |